Abiopharma

🔍 SCHLEIFER LEONARD S (Director)

Company: REGENERON PHARMACEUTICALS, INC. (REGN)

Report Date: 2025-12-09

Detailed Transactions and Holdings:

• Acquired 172,723 shares of Common Stock at $555.67 per share (Direct)
  Date: 2025-12-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 369,668.00 | transaction_form_type: 4
• Sold 155,145 shares of Common Stock at $701.51 per share (Direct)
  Date: 2025-12-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 214,523.00 | transaction_form_type: 4
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-12-09 | Code: H | nature_of_ownership: By 2024 GRAT | shares_owned_after: 127,484.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-12-09 | Code: H | nature_of_ownership: By 2025 GRAT | shares_owned_after: 300,000.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-12-09 | Code: H | nature_of_ownership: By 401(k) Plan | shares_owned_after: 5,989.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-12-09 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 39,985.00
• Sold 172,723 shares of Non-Qualified Stock Option (right to buy) at $555.67 per share (Derivative)
  Date: 2025-12-09 | Code: M | Expires: 2025-12-16 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The stock option award vested in four equal annual installments, commencing one year after the date of grant.